Search for a trial | Research with human participants

3 results

A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis.

Approved WMOCompleted

To evaluate the long-term safety of FAB122 in patients with ALS.

A multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of FAB122 in patients with Amyotrophic Lateral Sclerosis

Approved WMORecruitment stopped

To assess the effect of treatment with 100 mg of FAB122 (edaravone) on disease progression in patients with ALS.

A multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of FAB122 in patients with Amyotrophic Lateral Sclerosis.

Not approvedWill not start

To assess the effect of treatment with 100 mg of FAB122 (edaravone) on disease progression in patients with ALS.